Mathilde Guerin

TL;DR: Combining buparlisib and lapatinib in HER2-positive trastuzumab-resistant advanced breast cancer was feasible and preliminary evidence of antitumour activity was observed in this heavily pre-treated population.

TL;DR: Questions remain unresolved, like the optimal management of HER2-positive/HR-positive advanced breast cancer and the identification of predictive biomarkers to better define populations that can benefit most from these new therapies and approaches.

TL;DR: Parallel reaction monitoring-based assay, developed to quantify proteins of the HER2 pathway in breast cancer samples revealed a large magnitude of expression, which may have relevance in terms of treatment sensitivity.

TL;DR: This indication is indicated as single-agent in taxane and trastuzumab-pretreated HER2-positive breast cancer patients with metastatic and locally recurrent unresecable disease or relapsing within 6 months of the end of adjuvant therapy.

TL;DR: This review will present novel proteomics technologies such as Reverse Phase Protein Array (RPPA) or mass-spectrometry (MS) based approaches that have emerged and that could progressively replace old-fashioned methods to validate proteins as diagnostic, prognostic or predictive biomarkers, and eventually monitor them in the routine practice.